Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013
Cash flows from operating activities:
Net loss	$ (268,000)	$ (925,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	174,000	222,000
Amortization of intangible assets	205,000	250,000
Amortization of debt discount	39,000	47,000
Stock based compensation expense	21,000	29,000
Change in fair value of warrant liability	(45,000)	196,000
Non cash foreign currency translation loss		32,000
Changes in operating assets and liabilities:
Accounts receivable – net	72,000
Inventories	64,000	(450,000)
Prepaid expenses and other assets	(340,000)	48,000
Accounts payable and accrued expenses	(433,000)	88,000
Net cash used in operating activities	(511,000)	(463,000)
Cash flows from investing activities:
Capital expenditures	(85,000)	(31,000)
Proceeds from sale of property and equipment	125,000
Patent expenditures	(35,000)	(64,000)
Net cash provided by or (used in) investing activities	5,000	(95,000)
Cash flows from financing activities:
Net proceeds or (payments) on bank line of credit	(853,000)	922,000
Payments on bank term loan	(56,000)	(84,000)
Payments on MEDC/MSF term loans		(136,000)
Payments on PFG term loan	(180,000)	(178,000)
Payments on capital leases	(6,000)
Net proceeds for issuance of Class A Common Stock	2,914,000
Net cash provided by financing activities	1,819,000	524,000
Effect of exchange rate changes on cash and cash equivalents		(4,000)
Net increase or (decrease) in cash and cash equivalents	1,313,000	(38,000)
Cash and cash equivalents at beginning of period	120,000	619,000
Cash and cash equivalents at end of period	1,433,000	581,000
Supplemental disclosure of cash flow information:
Cash paid for interest	97,000	92,000
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of equipment through capital lease		$ 50,000